Clinical value of combined detection of serum PGⅠ, PGⅡ, PGR, G-17 and IgG anti-Hp in the diagnosis of early gastric cancer

Abstract

Abstract:

ObjectiveTo investigate the clinical value of combined detection of serum pepsinogen (PG)Ⅰ, PGⅡ, PGⅠ/PGⅡ (PGR), gastrin-17 (G-17) and IgG anti-Helicobacter Pylori(IgG anti-Hp) in the diagnosis of early gastric cancer.MethodsOne hundred and twenty patients with gastric cancer (early gastric cancer group), 60 patients with atrophic gastritis (atrophic gastritis group) and 120 healthy volunteers (control group) who were examined or treated in our hospital from January 2018 to June 2019 were selected as the subjects. The levels of serum PGⅠ, PGⅡ, PGR, G-17 and IgG anti-Hp were compared among the three groups. The indicators and combined diagnostic value were analyzed by receiver operating characteristic (ROC) curve.ResultsThe levels of PGⅠ in early gastric cancer group, atrophic gastritis group and control group were (59.85±8.59)ng/ml, (72.19±9.89)ng/ml, (96.83±8.66)ng/ml, with statistically significant difference (F=530.504,P<0.001). The levels of PGⅡ in the three groups were (23.19±2.45)ng/ml, (20.60±4.19)ng/ml, (16.52±3.34)ng/ml, with statistically significant difference (F=130.085,P<0.001). The levels of PGR in three groups were 2.78±0.69, 4.33±0.95, 6.21±1.46, with statistically significant difference (F=288.801,P<0.001). The levels of G-17 in the three groups were (77.04±10.09)ng/ml, (64.69±7.22)ng/ml, (55.91±8.32)ng/ml, with statistically significant difference (F=170.770,P<0.001). The levels of IgG anti-Hp in the three groups were (70.23±8.11)IU, (58.30±9.37)IU, (33.00±5.24)IU, with statistically significant difference (F=778.431,P<0.001). The levels of serum PGⅠand PGR in early gastric cancer group and atrophic gastritis group were significantly lower than those in control group (allP<0.05). The levels of serum PGⅠand PGR in early gastric cancer group were significantly lower than those in atrophic gastritis group (bothP<0.05). While serum PGⅡ, G-17 and IgG anti-Hp in early gastric cancer group and atrophic gastritis group were significantly higher than those in control group (allP<0.05). The levels of PGⅡ, G-17 and IgG anti-Hp in gastric cancer group were significantly higher than those in atrophic gastritis group (allP<0.05). According to the ROC curve, the critical value of serum PGⅠ diagnosis was 73.11 ng/ml, the sensitivity was 63.33%, the specificity was 83.33%, and the area under the curve (AUC) was 0.801. The critical value of serum PGⅡ diagnosis was 19.55 ng/ml, the sensitivity was 75.83%, the specificity was 72.22%, and the AUC was 0.760. The critical value of serum PGR diagnosis was 4.60, the sensitivity was 82.50%, the specificity was 77.22%, and the AUC was 0.816. The critical value of serum G-17 diagnosis was 64.33 ng/ml, the sensitivity was 64.17%, the specificity was 65.56%, and the AUC was 0.631. The critical value of IgG anti-Hp diagnosis was 53.80 IU, the sensitivity was 59.17%, the specificity was 75.00%, and the AUC was 0.708. At the critical tangent point, the sensitivity, specificity and AUC of PG I + IgG anti-Hp were 69.17%, 76.67% and 0.754 respectively; the sensitivity, specificity and AUC of PGR + IgG anti-Hp were 88.33%, 74.44% and 0.798 respectively; the sensitivity, specificity and AUC of G-17 + IgG anti-Hp were 71.67%, 65.56% and 0.718 respectively. The sensitivity of joint detection of the five indexes was 92.50%, the specificity was 72.22%, and the AUC was 0.869. The sensitivity of joint detection was significantly higher than that of individual detection (allP<0.05), and the AUC of joint detection was significantly higher than that of individual indexes (Z=1.848,P=0.032;Z=3.145,P=0.001;Z=1.688,P=0.046;Z=7.726,P<0.001;Z=4.931,P<0.001;Z=3.188,P=0.001;Z=1.783,P=0.037;Z=4.534,P<0.001).ConclusionThe combined detection of serum PGⅠ, PGⅡ, PGR, G-17 and IgG anti-Hp can improve the sensitivity of gastric cancer diagnosis and it is of great significance and value for early diagnosis of gastric cancer.

Key words:Stomach neoplasms,Pepsinogens,Helicobacter Pylori,Gastrin-17

Yuan Peijie. Clinical value of combined detection of serum PGⅠ, PGⅡ, PGR, G-17 and IgG anti-Hp in the diagnosis of early gastric cancer[J]. Journal of International Oncology, 2020, 47(1): 24-28.

Figures/Tables4

组别	性别 (男/女,例)	年龄 ( $x ?$ ±s, 岁)	体重指数 ( $x ?$ ±s, kg/m²)
早期胃癌组 (n=120)	84/36	57.11±3.91	22.07±2.35
萎缩性胃炎组 (n=60)	41/19	57.64±4.00	21.67±2.40
对照组 (n=120)	79/41	58.01±3.97	21.69±2.13
F/χ²值	0.483	0.977	0.723
P值	0.786	0.378	0.486

组别	PGⅠ(ng/ml)	PGⅡ(ng/ml)	PGR	G-17(ng/ml)	IgG anti-Hp(IU)
早期胃癌组(n=120)	59.85±8.59^ab	23.19±2.45^ab	2.78±0.69^ab	77.04±10.09^ab	70.23±8.11^ab
萎缩性胃炎组(n=60)	72.19±9.89^a	20.60±4.19^a	4.33±0.95^a	64.69±7.22^a	58.30±9.37^a
对照组(n=120)	96.83±8.66	16.52±3.34	6.21±1.46	55.91±8.32	33.00±5.24
F值	530.504	130.085	288.801	170.770	778.431
P值	<0.001	<0.001	<0.001	<0.001	<0.001

诊断指标	临界值	AUC	95%CI	标准误	敏感性 (%)	特异性 (%)	阳性预测值 (%)	阴性预测值 (%)	约登指数	Kappa值
PGⅠ	73.11 ng/ml	0.801^a	0.750~0.852	0.027	63.33^a	83.33^a	78.35^a	78.32^a	0.517	0.783
PGⅡ	19.55 ng/ml	0.760^a	0.707~0.812	0.024	75.83^a	72.22	64.54	81.76^a	0.481	0.737
PGR	4.60	0.816^a	0.768~0.864	0.019	82.50^a	77.22	71.72	89.68^a	0.639	0.810
G-17	64.33 ng/ml	0.631^a	0.645~0.772	0.018	64.17^a	65.56^a	55.40^a	73.29^a	0.297	0.650
IgG anti-Hp	53.80 IU	0.708^a	0.645~0.772	0.021	59.17^a	75.00	61.21	73.37^a	0.342	0.687
PGⅠ+Hp-IgG	-	0.754^a	0.713~0.799	0.026	69.17^a	76.67	66.40	78.86^a	0.458	0.737
PGR+Hp-IgG	-	0.798^a	0.789~0.832	0.031	88.33^a	74.44	69.73	90.54	0.628	0.800
G-17+Hp-IgG	-	0.718^a	0.646~0.781	0.022	71.67^a	65.56^a	58.11^a	77.63^a	0.372	0.680
联合诊断	-	0.869	0.831~0.907	0.025	92.50	72.22	68.94	93.52	0.647	0.803
χ²值	-				73.862	35.006	22.579	46.899
P值	-				<0.001	<0.001	<0.001	<0.001

References15

[1]	Shitara K, Chin K, Yoshikawa T , et al. Phase Ⅱ study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage Ⅲgastric cancer after D2 gastrectomy[J]. Gastric Cancer, 2017,20(1):175-181. DOI: 10.1007/s10120-015-0581-1.
[2]	Park JY, Kim SG, Kim J , et al. Mo1121 Different clinical features distinguishing early from late metachronous gastric tumors after endoscopic submucosal dissection of early gastric cancer[J]. Gastrointest Endosc, 2017, 85(5): AB436. DOI: 10.1016/j.gie.2017.03.1013.
[3]	章静, 王贵峰, 李婉莹 , 等. 应用PCA-决策树模型评价胃泌素17与四种血清肿瘤标志物对胃癌的诊断价值[J]. 中华疾病控制杂志, 2018,22(8):867-870. DOI: 10.16462/j.cnki.zhjbkz.2018.08.028.
[4]	Cheung KS, Chan EW, Wong AYS , et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study[J]. Gut, 2018,67(1):28-35. DOI: 10.1136/gutjnl-2017-314605.
[5]	孙娜娜, 刘畅, 冯秋霞 , 等. 胃癌腹膜腔转移CT检查的影像学表现[J]. 中华消化外科杂志, 2017,16(11):1154-1159. DOI: 10.3760/cma.j.issn.1673-9752.2017.11.016.
[6]	刘婕, 贺海玲 . 胃癌超声造影参数ET、TTP水平与血管新生指标的相关性研究[J]. 实用癌症杂志, 2018,33(11):1767-1769. DOI: 10.3969/j.issn.1001-5930.2018.11.008.
[7]	Kotachi T, Ito M, Boda T , et al. Clinical significance of reddish depressed lesions observed in the gastric mucosa after helicobacter pylori eradication[J]. Digestion, 2018,98(1):48-55. DOI: 10.1159/000487045.
[8]	Lee SP, Lee SY, Kim JH , et al. Link between serum pepsinogen concentrations and upper gastrointestinal endoscopic findings[J]. J Korean Med Sci, 2017,32(5):796-802. DOI: 10.3346/jkms.2017.32.5.796.
[9]	钟华, 吴雪艳, 刘迪群 . 血清胃蛋白酶原Ⅰ、Ⅱ及比值联合Hp抗体检测对早期胃癌的诊断价值[J]. 重庆医学, 2017,46(6):821-823. DOI: 10.3969/j.issn.1671-8348.2017.06.032.
[10]	Zagari RM, Rabitti S, Greenwood DC , et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis[J]. Aliment Pharmacol Ther, 2017,46(7):657-667. DOI: 10.1111/apt.14248.
[11]	Corona G, Cannizzaro R, Miolo G , et al. Use of metabolomics as a complementary omic approach to implement risk criteria for first-degree relatives of gastric cancer patients[J]. Int J Mol Sci , 2018, 19(3). pii: E750. DOI: 10.3390/ijms19030750.
[12]	黄喜顺, 邓立新, 邱耀辉 . 血清PG、G-17联合CA72-4和13CUBT在早期胃癌的诊断价值[J]. 重庆医学, 2017,46(10):1346-1348. DOI: 10.3969/j.issn.1671-8348.2017.10.015.
[13]	沈玲, 朱海超, 杨秀丽 , 等. 胃癌患者Hp感染后P73与NF-κB和SOX2表达及临床病理特征的相关性研究[J]. 中华医院感染学杂志, 2018,28(15):2261-2264. DOI: 10.11816/cn.ni.2018-173205.
[14]	Wessler S, Krisch LM, Elmer DP , et al. From inflammation to gastric cancer-the importance of Hedgehog/GLI signaling in Helicobacter pylori-induced chronic inflammatory and neoplastic diseases[J]. Cell Commun Signal, 2017,15(1):15. DOI: 10.1186/s12964-017-0171-4.
[15]	Al-Ezzy AIA . Immunopathological and modulatory effects of Cag A + genotype on gastric mucosa, inflammatory response, pepsinogens, and gastrin-17 secretion in Iraqi patients infected with H. pylori [J]. Open Access Maced J Med Sci, 2018,6(5):794-802. DOI: 10.3889/oamjms.2018.178.